A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06092762
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
180
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
AK120
Sponsor
Akeso